TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8091168
Drug: OME/AMOX (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: OME/AMOX (oral OME 40 mg bid and AMOX solute 750 mg tid for 10 days)
Study: 8091168
Drug: OME (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: OME (20 mg per day for 20 days)
Study: 30013785
Drug: Lanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanthanum carbonate (375–3000 mg/day)
Study: 30013785
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (non-iron-based phosphate binders)
Study: 24101048
Drug: Dose-intensive temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose-intensive temozolomide
Study: 21816628
Drug: Glenohumeral (GH)
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glenohumeral (GH) steroid injection
Study: 21816628
Drug: Subacromial (SA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subacromial (SA) steroid injection
Study: 15560690
Drug: Garlic enteric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic enteric coated tablets for 3 months
Study: 11422249
Drug: amoxycillin‐clavulanate (13.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: amoxycillin‐clavulanate (13.3 mg/kg 3 times daily)
Study: 11422249
Drug: cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cefuroxime axetil (15 mg/kg twice daily)
Study: 9430448
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ID, 5 mg, orally)
Study: 8018953
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) treatment for less than 2 weeks
Study: 8018953
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) treatment for 2 weeks or more
Study: 8018953
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) treatment
Study: 8018953
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) and N-desmethyltamoxifen (DMT) treatment
Study: 8018953
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) and N-desmethyltamoxifen (DMT) treatment after 2 weeks
Study: 3144446
Drug: Fluoride tablet
Normalized name: Sodium Fluoride Tablets
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride tablet programme (daily administration)
Study: 3144446
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no fluoride tablets)
Study: 29233783
Drug: 30-minute tDCS
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-minute tDCS combined with 50mg/day of sertraline
Study: 29233783
Drug: 20-minute tDCS
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-minute tDCS combined with 50mg/day of sertraline
Study: 17060567
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg once daily (QD)
Study: 16271726
Drug: Duloxetine 20
Normalized name: duloxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 20 mg twice daily (BID)
Study: 12825868
Drug: Prednisolone 50
Normalized name: prednisolone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 50 mg daily for 2 weeks
Study: 7045615
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy alone
Study: 6247521
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy and radiotherapy (including prophylactic brain irradiation in four patients)
Study: 28356133
Drug: Abdominal massage
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal massage once daily for 6 weeks
Study: 26240207
Drug: GARDASIL 9
Normalized name: Gardasil 9
DrugBank: Human papillomavirus type 58 L1 capsid protein antigen (DB10314)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GARDASIL 9 (9‐valent human papillomavirus [9vHPV] vaccine) administered concomitantly with MCV4/Tdap
Study: 26240207
Drug: MCV4/Tdap administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCV4/Tdap administered concomitantly with 9vHPV vaccine
Study: 26240207
Drug: Tdap administered
Normalized name: acellular pertussis vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap administered concomitantly with 9vHPV vaccine
Study: 12637608
Drug: TNX‐901 (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNX‐901 (450 mg)
Study: 12637608
Drug: TNX‐901 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNX‐901 (300 mg)
Study: 12637608
Drug: TNX‐901 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNX‐901 (150 mg)
Study: 10680434
Drug: Itraconazole solution
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole solution 800 mg day‐1
Study: 10680434
Drug: Itraconazole solution
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole solution 400 mg day‐1 (s/c1200)
Study: 10680434
Drug: Itraconazole solution
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole solution 400 mg day‐1 with loading dose of 800 mg day‐1 capsules for 7 days
Study: 10680434
Drug: Itraconazole solution
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole solution 400 mg day‐1
Study: 10680434
Drug: Itraconazole capsules
Normalized name: Itraconazole Capsules
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole capsules 400, 600 or 800 mg day‐1
Study: 8619361
Drug: Iobitridol (250-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iobitridol (250-300 mg)
Study: 7256696
Drug: Aspirin (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (0.6 g)
Study: 7256696
Drug: Dipyridamole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (150 mg)
Study: 31385041
Drug: Enoxaparin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (20 mg, twice daily), started 24-36 hours after surgery and continued until discharge
Study: 28596236
Drug: hyperinsulinemic hypoglycemia
Normalized name: Drugs for treatment of hypoglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: hyperinsulinemic hypoglycemia (bolus insulin)
Study: 28596236
Drug: hyperinsulinemic euglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: hyperinsulinemic euglycemia (bolus insulin and glucose infusion)
Study: 21114411
Drug: Intraurethral alprostadil
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraurethral alprostadil 125 to 250 μg daily for 9 months
Study: 21114411
Drug: Oral sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sildenafil citrate 50 mg daily for 9 months
Study: 15375810
Drug: Forced-use therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forced-use therapy (FUT) - wearing a thick constraint mitten on the sound arm for as many as 6 hours a day
Study: 11451210
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil 10-80 mg
Study: 11451210
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil 2.5-40 mg
Study: 7532497
Drug: Remantadine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remantadine (1.5 mg/kg body weight, 3 times a day for 3 days)
Study: 1071671
Drug: Intravenous labetalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous labetalol (1-5-2-0 mg/kg)
Study: 1071671
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of propranolol
Study: 31996613
Drug: Caffeine (280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (280 mg)
Study: 19760283
Drug: Caffeine (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (0 mg, placebo)
Study: 17138082
Drug: Landiolol 0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol 0 mg/kg (placebo)
Study: 17138082
Drug: Landiolol 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol 0.1 mg/kg
Study: 17138082
Drug: Landiolol 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol 0.2 mg/kg
Study: 17138082
Drug: Landiolol 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol 0.3 mg/kg
Study: 8940230
Drug: Combined PRP‐T/DTP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined PRP‐T/DTP vaccine
Study: 8940230
Drug: DTP vaccine
Normalized name: DTP Vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP vaccine only
Study: 1416161
Drug: GTN (glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTN (glyceryl trinitrate) infusion at 0.5 micrograms.kg‐1.min‐1
Study: 1416161
Drug: Stepwise increasing
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stepwise increasing infusion of GTN
Study: 2860284
Drug: Mérieux human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mérieux human diploid-cell-strain vaccine (HDCSV), 0.1 ml intradermally, at eight sites on day 0, at four sites on day 7, and at one site on days 28 and 91
Study: 2860284
Drug: Semple vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semple vaccine (SV)
Study: 2860284
Drug: Mérieux human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mérieux human diploid-cell-strain vaccine (HDCSV)
Study: 19841161
Drug: Lacosamide 200
Normalized name: lacosamide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide 200 mg bid alone
Study: 19841161
Drug: Lacosamide 200
Normalized name: lacosamide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide 200 mg bid with carbamazepine 200 mg bid
Study: 19841161
Drug: Carbamazepine 200
Normalized name: carbamazepine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine 200 mg bid alone
Study: 19841161
Drug: Carbamazepine 200
Normalized name: carbamazepine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine 200 mg bid with lacosamide 200 mg bid
Study: 18543427
Drug: HyperHaes (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: HyperHaes (combined hypertonic colloidal solution)
Study: 8713219
Drug: Zinc sulphate
Normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulphate capsules, 220 mg three times a day
Study: 2105070
Drug: Target PaCO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target PaCO2 corrected to patient's rectal temperature (mean 30.1, SD 1.9 degrees C)
Study: 417372
Drug: d-amphetamine at
Normalized name: amphetamine / dextroamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine at three dose levels
Study: 6805841
Drug: Controlled-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release morphine sulphate
Study: 30297322
Drug: Single-dose metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose metronidazole (2 g)
Study: 24644095
Drug: darunavir/cobicistat 800/150
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir/cobicistat 800/150 mg (FDC G003)
Study: 24644095
Drug: darunavir/cobicistat 800/150
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir/cobicistat 800/150 mg (FDC G004)
Study: 24644095
Drug: darunavir 800
Normalized name: darunavir 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir 800 mg and ritonavir 100 mg (single agents)
Study: 23923010
Drug: Paclitaxel therapy
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel therapy
Study: 19597418
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (specific programme of exercise therapy twice a day throughout the entire hospitalization phase)
Study: 17545373
Drug: Intradermal vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal vaccination at one fifth of a standard dose
Study: 17545373
Drug: Standard intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intramuscular vaccination
Study: 16287454
Drug: Sildenafil (25-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (25- or 50-mg, titrated to 100-mg)
Study: 16287454
Drug: Tadalafil (10-mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (10-mg, titrated to 20-mg)
Study: 216094
Drug: letosteine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: letosteine (50 mg t.i.d.)
Study: 216094
Drug: S‐carboxy‐methyl‐cysteine (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐carboxy‐methyl‐cysteine (750 mg t.i.d.)
Study: 27473629
Drug: IV and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV and perineural dexamethasone (1 ml of a 4 mg/ml dexamethasone solution)
Study: 27473629
Drug: IV dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV dexamethasone alone (8 mg)
Study: 21690303
Drug: Drug facts
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug facts format
Study: 19809205
Drug: Nifedipine controlled
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine controlled release (CR) 25 mg/day
Study: 17536870
Drug: Bramitob (300mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bramitob (300mg nebulized dose)
Study: 17536870
Drug: Tobi (300mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobi (300mg nebulized dose)
Study: 15297201
Drug: Platinum-based therapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based therapy
Study: 15297201
Drug: Combination platinum/paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination platinum/paclitaxel therapy
Study: 8439017
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg intravenous midazolam
Study: 31221679
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion threshold (transfuse if hemoglobin<7.5 g/dl)
Study: 31221679
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion threshold (transfuse if hemoglobin<9.5 g/dl in the operating room or ICU, or if hemoglobin<8.5 g/dl on the non-ICU ward)
Study: 31221679
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion threshold (transfuse if hemoglobin<7.5 g/dl) among patients with preoperative CKD
Study: 31221679
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion threshold (transfuse if hemoglobin<9.5 g/dl in the operating room or ICU, or if hemoglobin<8.5 g/dl on the non-ICU ward) among patients with preoperative CKD
Study: 27514371
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of solifenacin 5/10 mg + mirabegron 25/50 mg
Study: 27514371
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of solifenacin 10 mg + mirabegron 25 mg
Study: 27514371
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of solifenacin 5 mg + mirabegron 50 mg
Study: 25740286
Drug: Dose-dense chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense chemotherapy (administered intravenously every 2 weeks with pegfilgrastim support) with fluorouracil plus EC-P (FEC-P)
Study: 25740286
Drug: Dose-dense chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense chemotherapy (administered intravenously every 2 weeks with pegfilgrastim support) with EC-P
Study: 25740286
Drug: Standard-interval chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-interval chemotherapy (administered intravenously every 3 weeks) with FEC-P
Study: 25740286
Drug: Standard-interval chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-interval chemotherapy (administered intravenously every 3 weeks) with EC-P
Study: 25740286
Drug: Dose-dense chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense chemotherapy (every 2 weeks)
Study: 25740286
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of fluorouracil to chemotherapy
Study: 23328090
Drug: lersivirine 500
Normalized name: Lersivirine
DrugBank: Lersivirine (DB11649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lersivirine 500 mg once daily with tenofovir disoproxil fumarate/emtricitabine
Study: 23328090
Drug: lersivirine 750
Normalized name: Lersivirine
DrugBank: Lersivirine (DB11649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lersivirine 750 mg once daily with tenofovir disoproxil fumarate/emtricitabine
Study: 23328090
Drug: efavirenz 600
Normalized name: efavirenz 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: efavirenz 600 mg once daily with tenofovir disoproxil fumarate/emtricitabine
Study: 23328090
Drug: lersivirine 500
Normalized name: Lersivirine
DrugBank: Lersivirine (DB11649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lersivirine 500 mg
Study: 23328090
Drug: lersivirine 750
Normalized name: Lersivirine
DrugBank: Lersivirine (DB11649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lersivirine 750 mg
Study: 16435117
Drug: Fixed pharmaceutical
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed pharmaceutical budgets
Study: 12742982
Drug: Aspirin (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (160 mg qd for 7 days)
Study: 8888744
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl (TF) at doses of 25 or 50 micrograms/h
Study: 6325864
Drug: Nocardia rubra
Normalized name: Rhodotorula rubra
DrugBank: Rhodotorula rubra (DB10442)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nocardia rubra cell-wall skeleton (N-CWS) treatment
Study: 6325864
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no N-CWS treatment)
Study: 31500849
Drug: Remote ischaemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote ischaemic conditioning treatment (intermittent ischaemia and reperfusion applied to the arm through four cycles of 5‐min inflation and 5‐min deflation of an automated cuff device)
Study: 31500849
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (including a sham simulated remote ischaemic conditioning intervention at UK sites only)
Study: 28230557
Drug: Conventional Dresden
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Dresden protocol (3 mW/cm for 30 min, dose 5.4 J/cm)
Study: 28230557
Drug: Accelerated protocol
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated protocol (30 mW/cm for 3 min 40 s, dose 6.6 J/cm)
Study: 23700932
Drug: Methyldioxotetrahydropyrimidine sulfonisonicotinoyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldioxotetrahydropyrimidine sulfonisonicotinoyl hydrazide (MSH) at a daily dose of 800-1200 mg for 2-5 months
Study: 23700932
Drug: MSH on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSH on drug susceptible MBT
Study: 23700932
Drug: MSH on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSH on drug resistant MBT (isoniazid MIC of 1 mcg/ml)
Study: 23700932
Drug: MSH on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSH on isoniazid resistant MBT at 10 mcg/ml
Study: 16121879
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL bupivacaine 0.25% intraperitoneal spray
Study: 16121879
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL bupivacaine 0.25% intraperitoneal spray mixed with 200 mg ketoprofen
Study: 16121879
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL bupivacaine 0.25% intraperitoneal spray and intravenous 200 mg ketoprofen
Study: 16121879
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ketoprofen intravenously
Study: 11876691
Drug: Low-dose azathioprine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose azathioprine (< 2 mg/kg)
Study: 10438404
Drug: Vaginal micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal micronized progesterone (100 mg x 2/day)
Study: 10438404
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized progesterone (200 mg x 4/day)
Study: 7793869
Drug: Cefuroxime axetil,
Normalized name: Cefuroxime Axetil, 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime axetil, 500 mg twice daily for 20 days
Study: 7793869
Drug: Doxycycline, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline, 100 mg three times daily for 20 days
Study: 6383111
Drug: Ergometrine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergometrine 0.25 mg
Study: 6383111
Drug: Syntocinon 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syntocinon 10 mg
Study: 25844756
Drug: Lurasidone 20-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 20-60 mg
Study: 25844756
Drug: Lurasidone 80-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 80-120 mg